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WNT5A is an extracellular glycoprotein that activates several Wnt signaling 
pathways important in cancer. Significantly, Wnt5a expression is altered in numerous 
cancers. Little is known about Wnt5a gene regulation but current data indicate that 
misregulation of Wnt5a expression involves non genetic changes.  The goal of this study 
was to characterize transcriptional regulation from two alternate Wnt5a promoters, A and 
B.  To analyze the relative level of expression from the human Wnt5a alternative 
promoters, promoter-luciferase reporter constructs containing different amounts of 
upstream sequence from promoters A and B were transiently transfected into NIH3T3 
and Caco-2 cell lines.  The relative level of promoter activity was compared by 
measuring luciferase activity in the transfected cells.  Both Wnt5a promoters A and B 
were functional but found to have differential expression patterns in NIH3T3 and Caco-2 
cells, indicating both positive and negative regulatory sequences.   The transcription 
factor NFkappaB and the MAPK signaling pathway were studied to determine if they 
influence the transcriptional activity of Wnt5a promoters A and B.  Stable lines of 
NIH3T3 cells with Wnt5a promoters A and B were treated for 6 and 24 hours with 
TNFalpha, a known inducer of NFkappaB activity, and inhibitors of MAPK pathway 
kinases (MEK1/2 and ERK).  The cells were collected and assayed for firefly luciferase 
activity (relative light units) and standardized to DNA content.  TNFalpha slightly 
increased promoters A and B activity at 6 hrs.  TNFalpha had little or no effect on 
promoter A at 24 hours, whereas promoter B activity increased between 1.28 and 2.84 
 
 
fold.  The NFkappaB inhibitor, JSH-23, confirmed that NFkappaB is involved in the 
response of promoter B but not promoter A to TNFalpha.  MEK1/2 inhibitor had 
inconsistent effects on promoter A, whereas promoter B activity decreases at both time 
points.  ERK inhibitor increased promoter A activity for both 6 and 24 hours, whereas 
activity only increased for promoter B at 24 hours.  These findings were further examined 
by measuring the relative contribution of Wnt5a alternative promoter A and B 
endogenous transcripts in both NIH3T3 and GM03349.  Custom primers that amplify and 
detect human and mouse Wnt5a promoters A and B specific transcripts were created to 
analyze the relative amount of each transcript by qRT-PCR.  Results show that promoter 
A generates more transcripts than promoter B and that TNFalpha increases the activity of 
both promoters in mouse and human fibroblasts.  Overall, these data indicate that Wnt5a 
promoters A and B are differentially regulated and that NFkappaB influences 
transcriptional activity of Wnt5a promoter B rather than promoter A.   
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CHAPTER I 
 
INTRODUCTION 
 
 
Statement of Problem 
 
Cancer continues to be prevalent in the US with an estimated 11.7 million people 
living with the illness (American Cancer Society, 2007). It is a complex disease that 
results from both genetic and nongenetic molecular alterations in numerous cellular 
pathways involved in cell cycle and growth control, apoptosis, DNA repair, cell 
movement and cell adhesion.  One pathway often altered in transformed cancer cells is 
the Wnt signaling pathway.  In this study, the focus was on the Wnt ligand, WNT5A.  
WNT5A, a member of the Wnt protein family, is an extracellular glycoprotein that 
activates both the canonical and noncanonical pathways (McDonald and Silver, 2009).  
Wnt5a expression has been found to be altered in numerous cancers including lung, 
breast, thyroid, osteosarcoma, gastric, colorectal, leukemias, skin, pancreatic and prostate 
(reviewed in Katoh and Katoh, 2009).  While Wnt5a has been shown to be down 
regulated in several cancers such as colon and breast cancer (Ying et al., 2008; Leris et 
al., 2005),  it has also been shown to be over expressed in gastric and pancreatic cancer 
(Kurayoshi et al., 2006; Ripka et al., 2007).  Thus, it can function as either an oncogene 
or tumor suppressor.  Significantly, over expression of Wnt5a has been associated with 
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metastasis in pancreatic cancer (Ripka et al., 2007) and melanoma (Weeraratna et al., 
2002).  Current published data indicate that changes in Wnt5a expression during cancer 
progression do not involve genetic (DNA) changes such as gene mutation, amplification, 
or deletion but rather non genetic, epigenetic changes and alterations in various signaling 
pathways.   
Little is known about how the Wnt5a gene is regulated, however, there is some 
evidence that NFkappaB can influence Wnt5a expression.  NFkappaB is a transcription 
factor that mediates many genes that influence growth and inflammation and has been 
shown to be upregulated in cancer (Basseres and Baldwin, 2006), possibly due to its 
proinflammatory nature.  In this study we determined if Wnt5a expression changes with 
increased NFkappaB activity.  In addition, we examined the role of the MAPK pathway 
in Wnt5a expression, as MAPK signaling is often altered in transformed cells. For these 
studies, we analyzed transcription from two of the Wnt5a alternative promoters in both 
mouse and human cells to determine the relative contribution of each promoter to total 
Wnt5a transcript levels.  These alternative promoters were also characterized using 
promoter- reporter vectors.  Results from these studies have increased understanding of 
Wnt5a transcriptional regulation and its altered expression in transformed cells. 
 
Wnt Signaling and Wnt5a 
Wnts are a class of 19 extracellular secreted proteins that play a role in 
development, proliferation and apoptosis (Nishita et al., 2010).  They are hydrophobic 
signal peptides with no transmembrane domain.  Wnts are typically ligands for the 
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Frizzled (Fzd) receptor and low density lipoprotein receptor-related proteins (LPR) but 
do not solely signal through these receptors.  There are two classes of Wnt proteins: 
canonical, which results in an increase of beta-catenin through a signal transduction 
pathway, and non-canonical, which is any pathway that does not result in an increase of 
beta-catenin.  Wnt activation through the canonical pathway is vital for normal animal 
development, while deregulation of this pathway can result in cancer cell proliferation 
and cell migration. Non-canonical Wnts are known to antagonize canonical Wnts and 
control morphogenic movements through activation of the planar cell polarity (PCP) 
pathway and the Wnt Ca
2+
 signaling pathway (McDonald and Silver, 2009).  Although 
other Wnts have been studied and linked to cancer, including Wnt 1, 3, and 7, WNT5A 
has more recently been shown to be altered in transformed cells (Pukrop and Binder, 
2008).  WNT5A has traditionally been known to signal through the non-canonical 
pathway; however, recently WNT5A has also been shown to signal in canonical 
pathways (Nishita et al., 2010; McDonald and Silver, 2009).  Because WNT5A seems to 
signal multiple pathways, establishing it to be a cancer suppressor or proliferator has been 
difficult.   
 
Wnt5a’s Involvement in Cell Function and Development 
WNT5A has several normal physiological roles that may indicate its role in 
cancer development and progression.  WNT5A plays a role in mesenchymal 
differentiation, colon epithelial development, cell movement and morphogenesis (Pukrop 
and Binder, 2008).   Yamaguchi et al. (1999) explored the importance of Wnt5a 
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expression in the outgrowth structures of mouse embryos.  They detected Wnt5a in the 
distal parts where limbs, digits and face outgrowths are located.  They also created mice 
with an inactive Wnt5a gene, which died shortly after being born.  These embryos were 
examined and were found to have truncated limbs and underdeveloped digits as a result 
of decreased progenitor cell proliferation.  Thus, Wnt5a may function as a regulator of 
cell division during development, providing evidence for its role in cancer development 
and progression.  More recently, Wnt5a has also been shown to be involved in 
adipogenesis and promote adipocyte differentiation (Nishizuka et al., 2008).  
Interestingly, obese adipose tissues have higher levels of Wnt5a secretion resulting in 
increased insulin resistance through activated JNK1 and proinflammatory cytokines 
release from active macrophages (Oh and Olefsky, 2010).  Wnt5a also contributes to 
central nervous system maturation by  regulating midbrain morphogenesis (Andersson et 
al., 2008), stimulating synaptic differentiation (Varela-Nallar et al., 2010), inducing 
cortical axon outgrowth (Li et al., 2010), and promoting interneuron progenitors 
differentiation (Paina et al., 2011).  Wnt5a has also been shown to be involved  in 
prostate gland development (Huang et al., 2009), gastrulation (Hardy et al., 2008), 
intestinal elongation (Cervantes et al., 2009), and chondrocyte proliferation (Yang et al., 
2003).   
 
Wnt5a and Cancer 
Wnt5a expression has been found to be altered in numerous cancers including 
lung, breast, thyroid, osteosarcoma, gastric, colorectal, leukemias, skin, pancreatic and 
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prostate (reviewed in Katoh and Katoh, 2009).  While Wnt5a has been shown to be down 
regulated in several cancers such as colon and breast cancer (Ying et al., 2008; Leris et 
al., 2005), it has also been shown to be over expressed in gastric and pancreatic cancer 
(Kurayoshi et al., 2006; Ripka et al., 2007).  Thus, Wnt5a can function as either an 
oncogene or tumor suppressor.  Significantly, over expression of Wnt5a has been 
associated with metastasis in pancreatic cancer (Ripka et al., 2007) and melanoma 
(Weeraratna et al., 2002).  In one particular article, Weeraratna et al. (2002) examined the 
role of Wnt5a in melanoma metastasis.  Melanoma cells from a patient were transfected 
with vectors that constitutively express Wnt5a.  These cells showed increased PKC 
(protein kinase C) activity, a protein known to play a role in cytoskeleton changes and 
cell motility. In addition to measuring PKC activity, Weeraratna et al. also studied the 
effects of reduced Wnt pathway activity.  Using an antibody against Frizzled-5, the 
WNT5A receptor, they were able to disrupt Frizzled-5/WNT5A interaction in the Wnt5a 
transfected cells and in other cells that have high endogenous Wnt5a expression. The 
cells treated with the antibody were shown to have decreased motility in scratch assays 
and in the Boyden chamber invasion assay.  The cells that were treated with the Frizzled-
5 antibody were also shown to have decreased activity of PKC.  These studies strongly 
suggest a role of Wnt5a in cell movement during metastases. 
In osteosarcoma cells, signaling by WNT5A through the noncanonical pathway 
Ror2 receptor was shown to be responsible for invasiveness of the osteosarcoma cells 
(Ren et al., 2011; Enomoto et al., 2009).  Suppressed expression of either WNT5A or 
Ror2 in the osteosarcoma cells inhibited invasiveness, including decreased invadopodia 
6 
 
formation (Enomoto et al., 2009).  In another study, WNT5A was shown to be bound to 
Frizzled2 at the edge of migrating cells and to regulate focal adhesion (Matsumoto et al., 
2010).  Also, Wnt5a expression is upregulated during epithelial-mesenchymal transition 
in human squamous carcinoma cells (Taki et al., 2003).  These studies suggest that Wnt5a 
contributes to metastasis by regulating adhesion junctions, invasiveness, and regulating 
the epithelial-mesenchymal transition. 
It is not clear, however, why Wnt5a expression is upregulated in some cancers 
and downregulated in others.  One suggestion is that the tumor cell type and 
microenvironment coupled with the complex regulation of Wnt5a, involving multiple 
pathways and epigenetic mechanisms, leads to these different responses of Wnt5a 
(Pukrop and Binder, 2008).  It is also possible that Wnt5a expression varies during 
transformation such that during progression, Wnt5a is upregulated when the tumor cells 
become metastastic.  Regardless, a more complete analysis of the Wnt5a gene regulatory 
region and its transcriptional regulation will provide insights in to how the gene is 
misregulated during tumorigenesis. 
 
Wnt5a Gene Structure and Regulation 
The gene for human Wnt5a is located between 55,499,744 and 55,521,331 base pairs on 
the p14.3 band of chromosome 3 (Entrez; Gene ID 7474).  Multiple transcripts are 
generated from the Wnt5a transcription unit due to alternative splicing and distinct starts 
of transcription (Ensembl; figure 1).  One well described transcription unit has 5 exons 
and 4 introns, producing an mRNA approximately 5,855 nucleotides long (Ensembl; 
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ENST00000264634, figure 1).  The protein derived from this transcript has 380 amino 
acids.   The more well characterized promoter is located upstream of exon 1 of this 
Wnt5a transcription unit.  There is, however, evidence of another promoter located in the 
first intron of this transcript (ENST00000497027, figure 1).  These two promoters have 
different exon 1’s, referred to as 1a and 1b, but have exon 2, 3, 4 and 5 in common 
(figure 2).    
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Figure 1:  Human Wnt5a Transcripts.  The two transcription units analyzed in this 
study are boxed.  The ENST00000264634 transcript correlates with hpromoter A.  The 
ENST00000497027 transcript correlates with hpromoter B. 
Human chromosome 3 
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Figure 2:  Human Wnt5a Transcripts 1a and 1b.  Exon 1b is located in the intron of 
transcript 1a.  Exons 2, 3, 4, and 5 are the same for both transcripts.  
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In this study, the promoter associated with the transcript beginning at exon 1a is 
referred to as hpromoter A (h=human), whereas the promoter associated with exon 1b 
will be referred to as hpromoter B.  Distinct Wnt5a cDNAs have been isolated for 
transcripts derived from hpromoter A (NM_003392) and hpromoter B (AK290869), 
providing support for transcription from the alternate start sites.  The protein derived 
from the hpromoter B transcript lacks the first 15 amino acids of the hpromoter A protein 
(figure 3).  However, the final protein product is identical due to removal of the 
endoplasmic reticulum (ER) signal sequence found in both proteins.  Thus, the two 
alternate transcripts result in the same protein after translation and post translational 
modifications.   
Further evidence of a functional significance of alternative promoters is the 
homology between the human and mouse Wnt5a genes.  The mouse Wnt5a gene is 
located on chromosome 14 and has 5 exons as well.  The mouse Wnt5a has a similar gene 
structure as the human with multiple transcripts derived from both alternative splicing 
and transcription starts (figure 4). The 4273 base pair mRNA also results in a 380 amino 
acid protein.  There are two transcripts, #1a (Ensembl; ENSMUST00000063465) which 
is similar to the hpromoter A transcript, and #2 (Ensembl; ENSMUST00000112272) 
which is similar to hpromoter B transcript. The promoter associated with the transcript 
#1a will be referred to as mpromoter A and promoter associated with the transcript #2 
will be referred to as mpromoter B. Characteristics of the human and mouse Wnt5a gene 
are listed in table 1.  
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Figure 3:  Human Wnt5a Protein Sequences.  Isoform B lacks the first 15 amino 
acids found in isoform A.  However, these 15 unique amino acids are cleaved off 
during protein modification resulting in identical proteins.  
 
Isoform A – Human Wnt5a Promoter A (NM_003392) 
MKKSIGILSPGVALGMAGSAMSSKFFLVALAIFFS…. 
 
 
Unique to Isoform A 
 
Isoform B – Human Wnt5a Promoter B (AK290869) 
 
MAGSAMSSKFFLVALAIFFS 
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Figure 4:  Mouse Wnt5a Transcripts.  The two transcription units analyzed in this 
study are boxed.  The ENSMUST00000063465 mouse transcript (#1A) correlates with 
hpromoter A, which we refer to as mpromoter A.  The ENSMUST00000112272 (#2) 
mouse transcript correlates with hpromoter B which we refer to as mpromoter B. 
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A comparison of the 4000 bp sequences upstream of the hpromoter A transcription unit to 
4000 bp sequences upstream to the mouse transcript #1a start of transcription reveals 
little homology (figure 5).  However, the mouse exon 1 is larger than the human exon 1 
and extends further upstream.  Consequently, a comparison was made between 1400 bp 
upstream of the ATG, start of translation, in exon 1 of mouse and human Wnt5a 
transcript (figure 6).  There appears to be greater homology between a 500 bp region 
upstream of the human exon 1 and a region contained within mouse exon 1.   A 
comparison was also made between intron 1 of the mouse and human promoter A 
transcript.  This would include the promoter B exon 1b (figure 7).  The region of highest 
homology appears in the region including the promoter B exon 1 and near the splice 
junctions at both ends.  Together, these comparisons support the conclusion that the 
mouse and human Wnt5a share conserved regulatory sequences in the region of 
promoters A and B.  This suggests that the hpromoters A and B and the mpromoters A 
and B are functionally important and that they share regulatory sequences.  
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Table 1.  Comparison of Mouse and Human Wnt5a Genes 
1 
 Mouse Human 
Location Chromosome 14 
29,317,936-29,340,633 
Chromosome 3 
55,499,743-55,523,973 
Number of 
Transcripts 
7 7 
Direction of 
Transcription 
Forward Reverse 
Transcript size 
(bases) and ID 
2
 
7009 basepairs (ID-063465) 
3650 basepairs (ID-112272) 
6042 basepairs (ID-474267) 
1299 basepairs (ID-497027) 
Proteins 
Produced 
2 5 
Protein Length 
(AA)  and ID 
3
 
380 residues (ID-064878) 
360 residues (ID-107891) 
380 residues (ID-417310) 
365 residues (ID-420104) 
Number of 
Exons 
4
 
5 (ID-063465) 
5 (ID-112272) 
5 (ID-474267) 
5 (ID-497027) 
 
1
Source: Mouse Wnt5a ENSMUSG00000021994 and Human ENSG00000114251.  
2
 For 
the two transcripts analyzed in this study.  Transcript ID is preceded by 
ENSMUST000000.  
3
 Derived from the two transcripts analyzed.
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Figure 5:  No Homology Between Human and Mouse Promoters A and B 4000 bp 
Upstream.  This graph was generated using the MacVector Pustnell DNA matrix 
application.  Homologous regions are indicated by the dark lines or spots on the 
diagonal.   
 
16 
 
Figure 6:  Homology Between Human and Mouse Promoter A.  Comparison 
between 1400 bp upstream of the ATG start of translation of mouse and human Wnt5a 
corresponds with Promoter A.  This graph was generated using the MacVector 
Pustnell DNA matrix application.  Homologous regions are circled and indicated by 
the dark lines or spots on the diagonal.   
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Figure 7:  Homology Between Human and Mouse Promoter B.  Comparison 
between intron 1 of mouse and human Wnt5a corresponds with Promoter B.  These 
graphs were generated using the MacVector Pustnell DNA matrix application.  
Homologous regions are circled and indicated by the dark lines or spots on the 
diagonal.   
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Alterations in Wnt5a Expression 
Current published data indicate that changes in Wnt5a expression during cancer 
progression do not involve genetic (DNA) changes such as gene mutation, amplification, 
or deletion but rather non genetic, epigenetic changes and alterations in various signaling 
pathways (Ying et al., 2008).  The Wnt5a gene has been shown to be both hypo- and 
hypermethylated in various cancer types.  Hypermethylation of the Wnt5a gene has been 
shown in acute myeloid and lymphoblastic leukaemia (Martin et al., 2010; Roman-
Gomez et al., 2007) and colorectal cancer (Ying et al., 2008, Hibi et al., 2009), whereas 
hypomethylation has been shown in prostate cancer (Wang et al., 2007).  Wnt5a 
expression is also regulated by various transcription factors and signaling pathways.  
Transcription factors CUTL1 and PAX2 have been shown to bind to the Wnt5a promoter 
(Ripka et al., 2007; Tamimi et al., 2008) and activated Ras, a member of the mitogen 
activated protein kinase (MAPK) signaling pathway, has been shown to decrease Wnt5a 
expression (Bui et al., 1997).  In another study, SW480 cells, a human colon cancer cell 
line, underwent amino acid deprivation to induce the MAPK pathway (Wang and Chen, 
2009).  There was an increase of phosphorylated ERK1/2, which also led to a 
downregulated Wnt5a expression.  There is some limited evidence that NFkappaB 
influences Wnt5a expression.  NFkappaB is a transcription factor that mediates many 
genes that influence growth and inflammation and has been shown to be upregulated in 
cancer (Basseres and Baldwin, 2006), possibly due to its proinflammatory nature.  Ge et 
al. (2011) found that overexpression of NFkappaB induces Wnt5a expression.  
Furthermore, ChIP analysis showed NFkappaB has the ability to bind to the Wnt5a 
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promoter.  Wnt5a expression was also upregulated by TNFalpha, a known inducer of 
NFkappaB, in MKN45 cells derived from gastric cancer (Saitoh and Katoh, 2002).  These 
studies were either focused on the Wnt5a regulatory sequences upstream of hpromoter A 
exon 1 or general Wnt5a mRNA expression.  Recent bioinformatic analyses have 
identified some possible NFkappaB binding sites in both hpromoters A and B (Katoh and 
Katoh, 2009). However, in the literature there has been little exploration of hpromoter B 
and its associated regulatory sequences in relation to hpromoter A.   
 
Study Overview and Specific Aims 
 Wnt5a is important in development and differentiation and is involved in 
regulation of cell growth control, differentiation and movement. Expression of Wnt5a is 
often altered during tumorgenesis, due to nongenetic mechanisms.  In spite of its 
importance, current understanding of Wnt5a gene regulation is limited and questions 
remain.  In this study, I addressed some of these questions.  In particular, transcription 
from two of Wnt5a alternate promoters were analyzed from the endogenous gene and 
using a promoter-reporter vector.  Also, the role of the transcription factor NFkappaB and 
MAPK signaling pathway was examined.  Specifically, I had three aims: (1) analyze the 
relative level of expression from the human Wnt5a alternative hpromoters, A and B using 
luciferase reporter vectors; (2) determine the contribution of the transcription factor 
NFkappaB to transcription from Wnt5a alternative hpromoters A and B and involvement 
of the MAPK signaling pathway; and (3) determine the relative contribution of transcripts 
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from Wnt5a alternative promoters A and B to Wnt5a mRNA levels from the genomic 
Wnt5a gene sequences.
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
Cell Culture  
NIH3T3 mouse fibroblasts originally obtained from the American Type Culture 
Collection (ATCC, Manassas, VA) were plated in a T-75 flask (Falcon, Franklin Lakes, 
NJ) using DMEM (Mediatech, Herndon, VA), supplemented with 10% calf serum 
(Atlanta Biologicals, Lawrenceville, GA) and 1% penicillin/streptomycin (5000 I.U./mL 
and 5000 ug/mL) (MP Biomedicals, Solon, OH).  This complete medium is referred to as 
DMEM-C.  The cells were grown in a 37ºC and 5% carbon dioxide humidified incubator.  
The cells were collected by trypsinization when at 80% confluency.  Essentially, the cells 
were washed with Ca
2+
-Mg
2+
 free Hank’s (400 mg/L KCl, 60 mg/L KH2PO4, 350 mg/L 
NaHCO3, 8 g/L NaCl, 90 mg/L Na2HPO4·7H2O, 1 g/L D-glucose) and 4-5 mL 0.05% 
Trypsin and 0.53 mM EDTA was added.  After one minute, the cells were 
microscopically examined.  Once released from the plate, an equal volume of DMEM-C 
was added and the cell mixture transferred to a sterile 15 mL tube.  The cells were 
pelleted by centrifugation, and resuspended in 5 mL DMEM-C.  The cell density 
(cells/mL) was determined using a hemocytometer.  Cells were re-plated at different 
densities depending on the experiment.
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Caco-2, a human colorectal adenocarcinoma derived cell line, was obtained from 
ATCC. The Caco-2 cells were grown in RPMI 1640 medium (Sigma, St. Louis, MO) 
containing 10% fetal bovine serum (Gibco, Carlsbad, CA) and 1% 
penicillin/streptomycin (5000 I.U./mL and 5000 ug/mL) (MP Biomedicals, Solon, OH).  
The cells were cultured in a 37ºC and 5% carbon dioxide humidified incubator.  Caco-2 
cells were maintained at sub-confluence densities.  Cells were re-plated at 1x10
4
 cells per 
cm
2
.  Cells were collected as described for NIH3T3 with the following exceptions:  The 
trypsin solution was 0.25% Trypsin and 1.0 mM EDTA and trypsinization was at 37ºC 
for 3 to 5 minutes.   
GM03349 cells are normal human dermal fibroblast cells obtained from National 
Institute of General Medical Sciences (NIGMS) Human Genetic Mutant Cell Repository 
(Corriell, Camden, NJ).  They are from a 10 year old male.  They were grown in 
Minimum Essential Medium (MEM) (Mediatech, Inc, Manassas, VA), supplemented 
with 10% fetal bovine serum (Gibco, Carlsbad, CA), 2 mM L-glutamine and 1% 
penicillin/streptomycin (5000 I.U./mL and 5000 ug/mL) (MP Biomedicals, Solon, OH). 
The cells were cultured in a 37ºC and 5% carbon dioxide humidified incubator. 
 
Transient Transfections and Dual Luciferase Assays 
NIH3T3 cells (6 x 10
4
 cells/well) and Caco-2 cells (4 x 10
4 
cells/well) were plated 
in 24-well plates (AGadvangene, Lake Bluff, IL) and incubated for 24 hours.  The 
hpromoter A and B constructs (0.5 ug) and the parental plasmid pGL4.17 (Promega, 
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Madison, WI) (0.5 ug) were transiently transfected into NIH3T3 cells using TransIT-LT 
(Mirus, Madison, WI) and Caco-2 using Nanojuice (Novagen, San Diego, CA), along 
with 10 ng of a Renilla control vector (pHRL-SV40) according to instructions.  Each 
construct was transfected into four wells of cells. After 24 hours the cells were collected.  
Essentially, the media was removed and the cells were washed with 1x Phosphate 
Buffered Saline (PBS) (NaCl 81%, Na2HPO4 ≈14%, KH2PO4 ≈3%, KCl ≈2%) (Fisher 
Scientific, Cat# BP661, Pittsburgh, PA).  The PBS was removed and 1x Passive Lysis 
Buffer (Promega, Madison, WI) was added to each well.  The samples were incubated at 
37ºC for 15 minutes and the entire plate placed at -80ºC.  When assayed, the plates were 
removed from the freezer and the samples allowed to thaw to room temperature.  20 uL 
of lysate from each sample was added to a black-sided 96 well plate (Corning Inc, 
Corning, NY) to be assayed for luciferase activity on a Synergy 2 multi-mode microplate 
reader (BioTek, Winooski, Vermont) using the Dual-Luciferase Assay System (Promega, 
Madison, WI).  The Dual-Luciferase Assay system was used to determine firefly and 
Renilla luciferase activity in the same sample.  The raw firefly RLU values for each 
sample was divided by the Renilla RLU values to control for DNA uptake during 
transfection.  The average firefly RLU/Renilla RLU value was graphed for each 
construct.  The standard error was determined for the four values for each construct.  The 
transfection was repeated three independent times using newly plated cells.  
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Treatment of Wnt5a Promoter A and B Stable Cell Lines 
 NIH3T3 cell lines stably transfected with the full length Wnt5a hpromoters A 
p2178and B p1981 reporter constructs were utilized in these studies.  These cells were 
plated in 48 well plate (AGadvangene Lifescience Plasticware, Lake Bluff, IL) at two 
different densities for the different treatments: 2x10
4
 cells per well for 6 hour treatments 
and 1.5 x10
4
 cells per well for 24 hour treatments.  The next day, the cells were treated 
with TNFalpha (Thermoscientific, Rockford, IL), dimethyl sulfoxide (DMSO) (ATCC), 
NFkappaB Activation Inhibitor II (JSH-23) (Santa Cruz Biotechnology, Santa Cruz, CA), 
1-fluoro-2-[2-(4-methoxyphenyl)ethenyl]-benzene (NFkappaB inhibitor CAY105512) 
(Cayman Chemical, Ann Arbor, MI), 3-(2-Aminoethyl)-5-((4-ethoxyphenyl)methylene)-
2,4-thiazolidinedione,HCl (ERK inhibitor) (Calbiochem, Gibbstown, NJ) or U01296 
(MEK 1/2 Inhibitor) (Promega, Madison, WI).  TNFalpha and the various inhibitors were 
added to tubes of fresh medium to their final concentrations.  The medium was removed 
from the cells and replaced with the appropriate medium plus TNFalpha and\or 
inhibitors.  The stock and final concentrations used in these studies were TNFalpha (1 
ng/ul; 5 ng/ml), JSH-23(40 mM; 30 uM), CAY105512 (10 mM; 1 uM), ERK inhibitor 
(40 mM; 25uM), U01296 (10 mM; 10 uM).  All compounds were prepared in DMSO 
with the exception of TNFalpha which was prepared in 1% BSA in PBS.  Control cells 
were either left untreated in studies of TNFalpha only or DMSO at the same percent 
concentration as the inhibitors.  Incubation was for 6 and 24 hours.  The cells were 
collected by removing the media and washing with 1x PBS.  100 ul of 1x Cell Lysis 
Buffer (Promega, Madison, WI) was added to each well and the entire plate placed at -
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80ºC.  When assayed, the plates were removed from the freezer and the samples allowed 
to thaw to room temperature.  20 ul of lysate from each sample was added to a black-
sided 96 well plate (Corning Inc, Corning, NY) to be assayed for luciferase activity 
(relative light units or RLUs) on a Synergy 2 multi-mode microplate reader (BioTek, 
Winooski, Vermont) using the Luciferase Assay System (Promega, Madison, WI) 
according to the manufacturer’s instructions.  Total DNA content was determined as a 
measure of cell number by assaying 20 ul of lysate using the CyQUANT NF Cell 
proliferation Assay (Invitrogen, Carlsbad, CA).  The RLUs were standardized to DNA 
content and results were graphed for comparison between the different treatments.  Each 
study was independently replicated 4-6 times.  Standard error values were determined 
and significance using the student t-test (p<0.05) for replicas. 
 
RNA Isolation and Real Time PCR 
 NIH3T3 cells and GM03349 cells were plated in 100 mm dishes.  After reaching 
80% confluency, the cells were treated with 5 ng/ml TNFalpha (Thermoscientific, 
Rockford, IL), ERK inhibitor (25 uM) (Calbiochem, Gibbstown, NJ) or MEK 1/2 
inhibitor U01296 (10 uM) (Promega, Madison, WI) for 6 and 24 hours as previously 
described.  The cells were collected by first washing them twice with cold PBS.  5 ml of 
cold PBS was added and the cells were scraped off the plate.  The cell suspension was 
transferred to a 15 ml conical tube and centrifuged at 3,000 RPM (1,000 x g) at 4 ºC for 5 
minutes in an IEC Centra GP8R centrifuge (ThermoScientific, Asheville, NC).  The 
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supernatant was removed and the cell pellet quick froze in liquid nitrogen and placed at -
80 ºC.  The total RNA was isolated from the cells using the SV Total RNA Isolation Kit 
(Promega, Madison, WI).  The concentration and 260/280 ratio was determined using the 
Take3 module on a Synergy 2 multi-mode microplate reader (BioTek, Winooski, 
Vermont).  1-3 ug of RNA was converted to cDNA using the QuantiTect Reverse 
Transcription kit (Qiagen, Valencia, CA) or the Maxima Reverse Transcriptase 
(Fermentas, Glen Burnie, Maryland).   
Quantitative RT-PCR was conducted using the Applied Biosystem TaqMan 
Assay (Applied Biosystems, Foster City, CA).  For NIH3T3 cells, primers used for 
amplification included mouse Wnt5a (Mm03053674_s1) and mouse cyclin D1 
(Mm00432358), which served as a positive control in the case of TNFalpha stimulation.  
In addition, custom primers were prepared that amplified mouse Wnt5a transcripts 
derived specifically from promoter A (AILJICZ) and promoter B (AIMSGI7).  For the 
human GM03349 cells, human Wnt5a (Hs00180103) and human cyclin D1 
(Hs00765553) were used, as well as custom human Wnt5a derived transcripts from 
promoter A (AIFARB5) and promoter B (AID1S5X).  Each amplification included 
internal control primers either GAPDH (mouse-Mm03302249_g1; human- Hs99999905), 
or ribosomal RNA (mouse-Mm01974474_gH; human-Hs01562845_s1).  A master mix 
for each target was prepared containing the 1x TaqMan Gene Expression Master Mix and 
primers.  This was aliquoted into separate tubes for each cDNA sample.  Sample cDNA 
was added and 10 ul pipetted into 3 wells of either a 48 or 96 well plate.  A test 
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amplification was generally conducted to determine the dilution factor for the cDNA.  
cDNA was diluted 1:2- 1:5 for most experiments. 
Quantitative RT-PCR was conducted on the Applied Biosystems StepOne Real 
Time PCR System thermal cycling block. Amplification conditions were 95ºC for 15 
seconds and 60ºC for 1 min for 40 cycles.  The CT (CT) value was determined for each 
cDNA sample using Microsoft Excel formula provided by R. Paules (National Institute of 
Environmental Health Sciences). CT (CT) is a measure of the relative level of 
transcripts, standardized to the endogenous control. 
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CHAPTER III 
 
RESULTS 
 
 
Relative Expression Levels of the Human Wnt5a Alternative Promoters, A and B   
 To examine the activity and regulation of the human Wnt5a alternative promoters 
A and B, deletion constructs previously created in the lab were used.  Wnt5a hpromoter A 
constructs containing fragments of 2178 bp, 1707 bp, 1358 bp, 773 bp and 425 bp were 
cloned upstream of the firefly luciferase gene of the pGL4.17-basic vector (figure 8).  
Likewise, similar constructs were created for hpromoter B containing fragments of 1981 
bp, 1257 bp, 817 bp and 356 bp (figure 8).  The location of these sequences within the 
Wnt5a genomic region and the primers used to generate the fragments for cloning are 
shown in Appendix A.  The hpromoter A and B deletion constructs and the empty pGL4-
basic were transiently transfected, along with a Renilla vector as a control for DNA 
uptake, into NIH3T3 (mouse fibroblast cells) and Caco-2 (human colorectal epithelial 
adenocarcinoma cells).   After 24-48 hours, the cells were collected and assayed for 
firefly and Renilla luciferase activity.  The firefly luciferase activity or relative light units 
(RLUs) was standardized to the Renilla RLUs for the same sample and graphed for 
comparison of each deletion construct’s relative expression in both cell types. 
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Figure 8.  Wnt5a hPromoters A and B Luciferase Reporter Constructs.  The numbers 
are base pairs (bp) upstream from the first nucleotide of the cDNA as indicated.  The 
hpromoter A fragments were cloned into pGL4.17 using a Hind III site, whereas Bgl II 
was used for hpromoter B fragments.  hPromoter B constructs contain a 412 bp intron.  
The scale bar applies only to the Wnt5a upstream sequences.  The sequence of the 
upstream regions can be found in Appendix A. 
  
30 
 
It is important to note that by cloning the hpromoter A and B gene regulatory 
regions separately into the luciferase reporter vector the transcriptional activity of these 
sequences are being analyzed independently.  Genomically, these sequence regions are 
linked. 
hPromoters A and B are active in both cell types at relatively the same level of 
activity.  A low level of activity was not detected for any of the hpromoter A and B 
constructs, indicating that 425 bp (hpromoter A) and 356 bp (hpromoter B) of sequence 
are sufficient for transcriptional initiation and relatively high level of expression.  
However, the level of activity varies between different cell types and amount of upstream 
sequence.  The hpromoter A constructs displayed a similar pattern of luciferase activity in 
both NIH3T3 and Caco-2 cells (figure 9).  The increased activity observed comparing the 
p2178 and p1707 constructs suggests that a negative acting sequence is contained in the 
removed 471 base pairs.  The p1358 and p773 constructs had similar levels of activity in 
both cell types that was 2-3 fold less than the p1707 construct.  This suggests the removal 
of a positive acting sequence in this region.  There was an increase in luciferase activity 
for the p425 construct, indicating the presence of a negative acting sequence in the 348 
base pair region between p773 and p425. 
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Figure 9. Transient Expression of Wnt5a hPromoter A Deletion Constructs in 
NIH3T3 and Caco-2 Cells. The cells were transfected with the hpromoter A deletion 
constructs (figure 8), and an empty PGL4-basic, along with a Renilla vector as a control 
for DNA uptake.  After 24-48 hours, the cells were collected and assayed for firefly 
luciferase and Renilla activity.  The firefly luciferase activity or RLUs were divided by 
the Renilla RLUs for the same sample and graphed for comparison of each deletion 
construct’s relative expression in both cell types.  Bars are the means +/- standard error.  
N=4 
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The hpromoter B constructs displayed distinctive patterns of activity in the 
NIH3T3 and Caco-2 cells (figure 10).  In the NIH3T3 cells, the pattern is more similar to 
hpromoter A.  There was an increase in activity of approximately 2-fold after removing 
724 base pairs (comparing constructs p1981 and p1257), that indicates the presence of a 
negative regulatory sequence in this region.  Removal of additional sequences (constructs 
p817 and p356) reduced activity to the level of the p1981 construct, suggesting that a 
positive sequence was removed between 1257- 817 base pairs of the total promoter.  In 
contrast to the hpromoter A p425 construct, the hpromoter B p356 construct did not 
display an increase relative to the longest, p1981 construct.   
In the Caco-2 cells there was increasing activity as more of the hpromoter B 
upstream sequences were removed, with maximal activity measured with the shortest 
construct, p356.  The level of activity for the p356 construct was approximately 5-fold 
greater than the largest construct, p1981.  This suggests that negative acting regulatory 
sequences are present in these three regions: 1981-1257, 1257-817, and 817-356.  As 
expected, there was minimal activity from the control vector (empty pGL4.17) for both 
cell types. 
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Figure 10. Transient Expression of Wnt5a hPromoter B Deletion Constructs in 
NIH3T3 and Caco-2 Cells.  The cells were transfected with the hpromoter B deletion 
constructs (figure 8), and an empty PGL4-basic, along with a Renilla vector as a control 
for DNA uptake.  After 24-48 hours, the cells were collected and assayed for firefly 
luciferase and Renilla activity.  The firefly luciferase activity or RLUs were divided by 
the Renilla RLUs for the same sample and graphed for comparison of each deletion 
construct’s relative expression in both cell types.  Bars are the means +/- standard error.  
N=4 
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These transfections were repeated four times in both cells.  hPromoter B 
constructs gave very consistent results.  hPromoter A results were more variable, but the 
data in figures 9 and 10 are representative. 
Overall, these data suggest there is complex regulation of both Wnt5a alternative 
hpromoters A and B, involving both positive and negative sequences.  Also, there are 
differential expression patterns in NIH3T3 and Caco-2 cells.  hPromoters A and B 
activities are more similar in NIH3T3 mouse fibroblast cells, whereas there is more 
distinction between hpromoters A and B in Caco-2 human intestinal epithelial cells.  
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Contribution of the Transcription Factor NFkappaB to Transcription From Wnt5a 
Alternative Promoters A and B 
 
 Previous literature has shown that there are potential NFkappaB binding sites in 
both Wnt5a promoters (Katoh and Katoh, 2009; Ge et al., 2011) and that TNFalpha 
increases Wnt5a expression (Saitoh and Katoh, 2002).  However, no one has confirmed 
the effect of TNFalpha on Wnt5a gene expression nor if both promoters A and B are 
affected.  This is important as NFkappaB is often over expressed in transformed cells and 
may alter Wnt5a transcription. Stable lines of NIH3T3 cells with Wnt5a hpromoter A 
p2178 and hpromoter B p1981constructs were utilized in these studies.  The cells were 
plated in multi-well plates and treated for 6 and 24 hours with 5 ng/ml of TNFalpha, a 
known inducer of NFkappaB expression. The cells were collected and assayed for firefly 
luciferase activity or RLUs.  The RLUs were standardized to DNA content, which is a 
measure of cell number.  This TNFalpha treatment experiment was repeated four times.  
The TNFalpha treated cells were standardized to control cells and the average fold 
change for all four trials was determined and graphed. 
hPromoter A stable lines showed an increase in activity after 6 hours TNFalpha 
stimulation, indicating a more direct effect of NFkappaB binding on promoter activity 
(figure 11).  However, there was a slight decrease in activity 24 hours after treatment.  It 
is important to note that because the luciferase enzyme has a 2 hour half life, luciferase 
activity is a reflection of how active the promoter is at the 24 hour time point, not an 
accumulation of activity over a 24 hour period.   
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Figure 11.  TNFalpha Effects on hPromoter A and B Activity.  Stable lines of 
NIH3T3 cells containing either the hpromoter A p2178 luciferase reporter construct or 
the hpromoter B p1981 luciferase reporter construct were treated with 5ng/ml of 
TNFalpha for 6 and 24 hours.  The cells were lysed and assayed for luciferase activity 
and DNA content determined.  Activity is expressed as RLU/DNA.  The TNFalpha 
treated cells were standardized to control cells and the average fold change for all four 
trials was determined and graphed. Bars are the average fold change +/- standard error. 
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hPromoter B activity showed an increase in activity at both 6 and 24 hours.  The average 
fold change was determined for the four trials.  At 6 hours there was average fold 
increase of 1.42 in hpromoter B activity.  At 24 hours the average increase in activity was 
1.93 fold. 
hPromoter A showed a more variable response to TNFalpha.  At 6 hours the 
average fold increase was 1.44.  At 24 hours, hpromoter A showed an average slight 
decrease of 0.85 fold.  These data suggest that hpromoter A and B both respond to 
TNFalpha at 6 hours but the effect is prolonged for hpromoter B over a 24 hour period. 
The TNFalpha signaling pathway can activate multiple pathways, in addition to 
the NFkappaB pathway.  To determine if NFkappaB activation is involved in the 
response of the Wnt5a hpromoters A and B to TNFalpha stimulation we used inhibitors 
of NFkappaB activation.  The Wnt5a hpromoter A and B luciferase reporter lines were 
treated with and without TNFalpha in the presence and absence of inhibitors JSH-23 (J) 
and CAY10512 (C).   J prevents NFkappaB translocation into the nucleus following its 
activation.  C is a polyphenolic trans-stilbene resveratrol analog.  It has been shown to 
block TNFalpha activation of NFkappaB, although the exact mechanism is not known.  
After 6 and 24 hours, the cells were collected and assayed for luciferase activity.  Values 
were plotted as RLUs.  Wnt5a hpromoter B had consistent and similar results at 6 and 24 
hours (figure 13).  As previously observed (see figure 11), TNFalpha causes an increase 
in luciferase at both 6 and 24 hrs.  Addition of the inhibitor JSH-23 reduced RLU’s to 
approximately the level of the DMSO control (figure 13).  This result suggests that the 
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response of hpromoter B to TNFalpha is due to NFkappaB. Unexpectedly, inhibitor C 
increased RLU’s both alone and with TNFalpha, although the increase was higher with 
TNFalpha.  The increase was approximately 2-fold at 6 hrs for TNFalpha plus C inhibitor 
and 1.5-fold with C only.  At 24 hr, the increase was approximately 4 fold with TNFalpha 
plus C inhibitor and 2 fold with C inhibitor only.   
There was a slight increase in RLU’s in the hpromoter A reporter cell lines treated 
with TNFalpha (figure 12).  Addition of J inhibitor did not reduce luciferase activity to 
control levels, as seen for hpromoter B but slightly increased activity.  This result 
suggests that NFkappaB is not responsible for the observed increase in hpromoter A 
activity by TNFalpha stimulation.  The response of the hpromoter A reporter cell line to 
inhibitor C was similar to hpromoter B; an increase in activity above DMSO treated 
control cells was detected in cells treated with TNFalpha plus C and C only treated cells. 
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Figure 12.  TNFalpha and NFkappaB Inhibitors Do Not Affect hPromoter A 
Activity.  Stable lines of NIH3T3 cells containing the hpromoter A p2178 luciferase 
reporter construct were treated with and without 5ng/ml TNFalpha in the absence and 
presence of 30 uM inhibitor JSH-23 (J) and 1 uM inhibitor CAY10512 (C) for 6 and 24 
hours.  The cells were lysed and assayed for luciferase activity and DNA content 
determined.  Activity is expressed as RLU/DNA.  Bars are +/- standard error. The 
asterisk indicates a significant difference between the treated and control (DMSO) 
(p<0.05) N=6. 
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Figure 13.  TNFalpha and NFkappaB Inhibitors Affect hpromoter B Activity.  
Stable lines of NIH3T3 cells containing the hpromoter B p1981 luciferase reporter 
construct were treated with and without 5ng/ml TNFalpha in the absence and presence of 
30 uM inhibitor JSH-23 (J) and 1 uM inhibitor CAY10512 (C) for 6 and 24 hours.  The 
cells were lysed and assayed for luciferase activity and DNA content determined.  
Activity is expressed as RLU/DNA.  Bars are +/- standard error. The asterisk indicates a 
significant difference between the treated and control (DMSO) (p<0.05) N=6 
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MAPK Signaling Pathway Involvement in Wnt5a Alternative Promoters A and B 
Activation 
The MAPK pathway is often over activated in transformed cells due to genetic 
modification of one or more pathway components and there is limited evidence Wnt5a is 
regulated by this pathway (Bui et al., 1997; Wang and Chen, 2009).  To determine if 
Wnt5a transcription from its alternate promoters is linked to the MAPK signaling 
pathway, stable lines of NIH3T3 cells with human Wnt5a hpromoter A p2178 and 
hpromoter B p1981constructs were utilized.  The cells were plated in multi-well plates 
and treated for 6 and 24 hours with ERK and MEK 1/2 (U0126) inhibitors along with a 
control treatment of DMSO.  The cells were collected and assayed for firefly luciferase 
activity or RLUs.  The RLUs were standardized to DNA content, which is a measure of 
cell number.  This treatment experiment was repeated at least four times.  The inhibitor 
treated cells were standardized to control cells and the average fold change for all trials 
were determined and graphed.  The assumption in this study is that the “constitutively” 
expressed Wnt5a in the fibroblast cells are responding to growth factor stimulation via 
MAPK signaling pathway.  Our working hypothesis is that inhibition of the MAPK 
pathway will cause a decrease in Wnt5a transcription from both or either alternative 
promoter.   
Treatment of hpromoter A p2178 NIH3T3 cell lines with the MEK 1/2 inhibitor 
U0126 gave variable results.  At 6 and 24 hours, there was essentially no effect on 
hpromoter A activity (figure 14).  However, ERK inhibitor treatment slightly increased 
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hpromoter A activity at 6 hours (average fold change 1.18).  At 24 hours there was a 
larger average fold increase in hpromoter A activity after ERK inhibitor exposure of 1.72.  
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Figure 14.  MEK 1/2 and ERK Inhibitor Effects on hPromoter A Activity.  Stable 
lines of hpromoter A p2178 NIH3T3 cells were plated and treated with either 10 uM 
MEK 1/2 inhibitor U0126 or 25 uM ERK inhibitor for 6 and 24 hours.  The cells were 
lysed in cell lysis buffer and assayed for luciferase activity.  Values were standardized to 
DNA content.  Activity is expressed as RLU/DNA.  The inhibitor treated cells were 
standardized to control cells and the average fold change for all trials were determined 
and graphed. Bars are the average fold change +/- standard error. N=6. 
0
0.5
1
1.5
2
2.5
6 hours 24 hours
A
v
er
a
g
e 
F
o
ld
 C
h
a
n
g
e
Time  Points
hPromoter A- ERK Inhibitor
(+) ERK Inhibitor
(+) DMSO for ERK Inhibitor
0
0.2
0.4
0.6
0.8
1
1.2
1.4
6 hours 24 hours
A
v
er
a
g
e 
F
o
ld
 C
h
a
n
g
e
Time Points
hPromoter A-MEK Inhibitor U0126
(+) MEK 1/2 Inhibitor
(+) DMSO for MEK 1/2 
Inhibitor
44 
 
MEK 1/2 inhibition also influenced hpromoter B activity.  At 6 hours there 
was a slight decrease in activity with an average fold change of 0.87 (figure 15).  At 
24 hours there was also a large decrease in hpromoter B activity with an average fold 
change of 0.64. 
hPromoter B activity in 6 hours ERK inhibitor treated cells essentially showed 
no change.  However, at 24 hours hpromoter B activity increased in ERK inhibitor 
treated cells with an average fold change of 2.04.
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Figure 15.  MEK 1/2 and ERK Inhibitor Effects on hpromoter B Activity.  Stable 
lines of hpromoter B p1981 NIH3T3 cells were plated and treated with either 10 uM 
MEK 1/2 inhibitor U0126 or 25 uM ERK inhibitor for 6 and 24 hours.  The cells were 
lysed in cell lysis buffer and assayed for luciferase activity.  Values were standardized to 
DNA content.  Activity is expressed as RLU/DNA.  The inhibitor treated cells were 
standardized to control cells and the average fold change for all trials were determined 
and graphed. Bars are the average fold change +/- standard error. N=6. 
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Relative Contribution of Transcripts from Wnt5a Alternative Promoters A and B in 
Treated and Untreated Cells 
We used hpromoter A and promoter B luciferase reporter vectors to analyze the 
activity from these alternative promoters independently of each other.  Genomically, the 
promoters are linked and it is possible that transcription from the two promoters are 
influenced by each other’s presence and additional genomic sequences.  For example, 
promoter A may predominate over promoter B and sequences located upstream promoter 
B, which is intron 1 for the promoter A transcript, may influence the activity of promoter 
A.  Thus, it is important to analyze the activities of promoter A and promoter B in situ 
from the genomic sequence.  
As previously discussed, there are Wnt5a transcript variants produced by the two 
different promoters.  Transcripts from hpromoter A includes exons 1a, 2, 3, 4, and 5, 
whereas transcripts from hpromoter B includes exons 1b, 2, 3, 4, and 5 (figure 2).  The 
mouse produces similar transcripts (figure 4).  Thus, the different isoforms of Wnt5a 
mRNA can be individually detected using transcript specific primers.  We designed 
TaqMan primer probes that would amplify and detect human and mouse Wnt5a promoter 
A and promoter B specific transcripts.  The location of the primers and probes in the 
cDNA sequences are shown in figures 16 and 17 for human and figures 18 and 19 for 
mouse.  The sequences of the primers and probe are in table 2.  The hpromoter A and B 
transcript specific primers were designed such that the forward and reverse primers flank 
a splice junction.  The hpromoter A primers amplify a 77 bp fragment including 
sequences in exon 1a and exon2.  The hpromoter B primers amplify a 71 bp fragment 
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including most of exon 1b and sequence in exon 2.  The mpromoter A and B primers are 
designed similarly to the human primers.  The promoter A primers generate a 85 bp 
product and promoter B primers a 62 bp product (table 2).  The correct product sizes 
were confirmed by DNA agarose gel electrophoresis for the mouse (C. Hsu, personal 
communication; data not shown).  
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Figure 16.  Human Wnt5a Promoter A Exon 1a-Exon 2 Fused Sequences.  The 
forward primer is shown in red, the probe in purple, and the reverse primer in blue.  The 
splice junction is denoted by an asterisk. 
 
        10         20         30         40         50         60 
AGTTGCCTGC GCGCCCTCGC CGGACCGGCG GCTCCCTAGT TGCGCCCCGA CCAGGCCCTG 
TCAACGGACG CGCGGGAGCG GCCTGGCCGC CGAGGGATCA ACGCGGGGCT GGTCCGGGAC 
 
        70         80         90        100        110        120 
CCCTTGCTGC CGGCTCGCGC GCGTCCGCGC CCCCTCCATT CCTGGGCGCA TCCCAGCTCT 
GGGAACGACG GCCGAGCGCG CGCAGGCGCG GGGGAGGTAA GGACCCGCGT AGGGTCGAGA 
 
       130        140        150        160        170        180 
GCCCCAACTC GGGAGTCCAG GCCCGGGCGC CAGTGCCCGC TTCAGCTCCG GTTCACTGCG 
CGGGGTTGAG CCCTCAGGTC CGGGCCCGCG GTCACGGGCG AAGTCGAGGC CAAGTGACGC 
 
       190        200        210        220        230        240 
CCCGCCGGAC GCGCGCCGGA GGACTCCGCA GCCCTGCTCC TGACCGTCCC CCCAGGCTTA 
GGGCGGCCTG CGCGCGGCCT CCTGAGGCGT CGGGACGAGG ACTGGCAGGG GGGTCCGAAT 
         Forward Primer 
       250        260        270        280        290        300
   
ACCCGGTCGC TCCGCTCGGA TTCCTCGGCT GCGCTCGCTC GGGTGGCGAC TTCCTCCCCG 
TGGGCCAGCG AGGCGAGCCT AAGGAGCCGA CGCGAGCGAG CCCACCGCTG AAGGAGGGGC 
 Probe 
       310        320     *  330        340        350       360 
CGCCCCCTCC CCCTCGCCAT GAAGAAGTCC ATTGGAATAT TAAGCCCAGG AGTTGCTTTG 
GCGGGGGAGG GGGAGCGGTA CTTCTTCAGG TAACCTTATA ATTCGGGTCC TCAACGAAAC 
       Reverse Primer 
       370        380        390        400       410        420 
GGGATGGCTG GAAGTGCAAT GTCTTCCAAG TTCTTCCTAG TGGCTTTGGC CATATTTTTC 
CCCTACCGAC CTTCACGTTA CAGAAGGTTC AAGAAGGATC ACCGAAACCG GTATAAAAAG 
 
       430        440        450 
TCCTTCGCCC AGGTTGTAAT TGAAGCCAAT TCTTGGTG 
AGGAAGCGGG TCCAACATTA ACTTCGGTTA AGAACCAC 
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Figure 17.  Human Wnt5a Promoter B Exon 1b-Exon 2 Fused Sequences.  The 
forward primer is shown in red, the probe in purple, and the reverse primer in blue.  The 
splice junction is denoted by an asterisk.
 Forward Primer    Probe       * 
        10         20         30         40         50         60 
CTCCTCTCGC CCATGGAATT AATTCTGGCT CCACTTGTTG CTCGGCCCAG AAGTCCATTG 
GAGGAGAGCG GGTACCTTAA TTAAGACCGA GGTGAACAAC GAGCCGGGTC TTCAGGTAAC  
        70         80         90        100        110        120 
GAATATTAAG CCCAGGAGTT GCTTTGGGGA TGGCTGGAAG TGCAATGTCT TCCAAGTTCT 
CTTATAATTC GGGTCCTCAA CGAAACCCCT ACCGACCTTC ACGTTACAGA AGGTTCAAGA 
Reverse Primer 
       130        140        150        160        170        180 
TCCTAGTGGC TTTGGCCATA TTTTTCTCCT TCGCCCAGGT TGTAATTGAA GCCAATTCTT 
AGGATCACCG AAACCGGTAT AAAAAGAGGA AGCGGGTCCA ACATTAACTT CGGTTAAGAA 
      
GGTG 
CCAC 
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Figure 18.  Mouse Wnt5a Promoter A Exon 1a-Exon 2 Fused Sequences.  The 
forward primer is shown in red, the probe in purple, and the reverse primer in blue.  The 
splice junction is denoted by an asterisk.
        Forward Primer   Probe          *      
        10         20         30         40         50         60 
CTTCGCTCGG GTGGCGACTT CCTCTCCGTG CCCCCTCCCC CTCGCCATGA AGAAGCCCAT 
GAAGCGAGCC CACCGCTGAA GGAGAGGCAC GGGGGAGGGG GAGCGGTACT TCTTCGGGTA 
        70         80         90        100        110        120 
TGGAATATTA AGCCCGGGAG TGGCTTTGGG GACCGCTGGA GGTGCCATGT CTTCCAAGTT 
ACCTTATAAT TCGGGCCCTC ACCGAAACCC CTGGCGACCT CCACGGTACA GAAGGTTCAA 
      Reverse Primer 
       130        140        150        160        170        180 
CTTCCTAATG GCTTTGGCCA CGTTTTTCTC CTTCGCCCAG GTTGTTATAG AAGCTAATTC 
GAAGGATTAC CGAAACCGGT GCAAAAAGAG GAAGCGGGTC CAACAATATC TTCGATTAAG 
 
TTGGTG 
AACCAC 
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Figure 19.  Mouse Wnt5a Promoter B Exon 1b-Exon 2 Fused Sequences.  The 
forward primer is shown in red, the probe in purple, and the reverse primer in blue.  The 
splice junction is denoted by an asterisk.
   
 Forward Primer *     Probe             
        10         20         30         40         50         60 
ACTTGTTGCT CCGGCCCAGA AGCCCATTGG AATATTAAGC CCGGGAGTGG CTTTGGGGAC 
TGAACAACGA GGCCGGGTCT TCGGGTAACC TTATAATTCG GGCCCTCACC GAAACCCCTG 
             Reverse Primer 
        70         80         90        100        110        120 
CGCTGGAGGT GCCATGTCTT CCAAGTTCTT CCTAATGGCT TTGGCCACGT TTTTCTCCTT 
GCGACCTCCA CGGTACAGAA GGTTCAAGAA GGATTACCGA AACCGGTGCA AAAAGAGGAA 
       130        140        150     
CGCCCAGGTT GTTATAGAAG CTAATTCTTG GTG 
GCGGGTCCAA CAATATCTTC GATTAAGAAC CAC 
 
 
 
 
 
 
5
2
 
 
 
 Sequence (5’-3’) 
Sequence Length Product 
Size (bp) 
Human Promoter A 
Forward Primer- TCGGGTGGCGACTTCCT 17 
77 Reverse Primer-CAACTCCTGGGCTTAATATTCCAAT 25 
Probe-CGCCCCCTCCCCCTCGCCATGAAG 24 
Human Promoter B 
Forward Primer- CCTCTCGCCCATGGAATT 18 
71 Reverse Primer- GGGCTTAATATTCCAATGGACTTC 24 
Probe- CTGGCTCCACTTGTTGCTCGGCC 23 
Mouse Promoter A 
Forward Primer- GTGGCGACTTCCTCTCCGT 19 
85 Reverse Primer- CGGTCCCCAAAGCCACT 17 
Probe- CCCCTCGCCATGAAGAAGCCCA 22 
Mouse Promoter B 
Forward Primer-ACTTGTTGCTCCGGCCC 17 
62 Reverse Primer-CGGTCCCCAAAGCCACT 17 
Probe- AGAAGCCCATTGGAATATTAAGCCCGG 27 
Table 2.  Sequence of Primers and Probes for qRT-PCR. 
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Our first study was to determine if TNFalpha treatment affects the level of human 
and mouse endogenous promoters A and B specific transcript using our custom TaqMan 
specific primers.  In addition, we wanted to determine the relative levels of promoters A 
and B transcripts in treated cells.  Both mouse fibroblasts (NIH3T3) and normal human 
fibroblasts (GM03349) were used to analyze the mouse and human Wnt5a genes.  The 
NIH3T3 and GM03349 cells treated with TNFalpha (5 ng/ml) for 6 and 24 hours.  Total 
RNA was isolated from cells and converted into cDNA for quantitative RT-PCR.  Each 
cDNA sample was amplified in triplicate using the following Applied Biosystems 
TaqMan primer sets.  Primers for the NIH3T3 cells include mouse Wnt5a, mouse cyclin 
D1 as a positive control of TNFalpha stimulation, custom mouse Wnt5a promoter A and 
promoter B derived transcripts primers, and ribosomal RNA as an internal control.  
Primers for the human GM03349 cells, include human Wnt5a and human cyclin D1 as a 
positive control of TNFalpha stimulation, custom human Wnt5a promoter A and 
promoter B derived transcripts primers, and GAPDH as an internal control.  These 
primers were used to analyze the relative amounts of each isoform by qRT-PCR using the 
Taqman system (Applied Biosystems).  The relative amount of each isoform was 
compared to the total amount of Wnt5a and to itself for treated and untreated samples.  
The CT (CT) value was determined for each cDNA sample.  This provides a measure 
of the relative level of transcripts, standardized to the endogenous control.  For example, 
Wnt5a relative transcript levels were measured in TNFalpha treated cells relative to 
untreated cells, using GAPDH or ribosomal RNA as internal controls.  A CT (CT) 
value of > 1 indicates an increase; =1 indicates no change and < 1 indicates a decrease.   
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First, we noted the cycle numbers for the Wnt5a, promoter A and promoter B 
transcripts in the NIH3T3 and GM03349 cells (table 3).  These results suggest that there 
are a greater number of promoter A than promoter B transcripts. In mouse, the promoter 
A cycle was one less than promoter B, indicating two times (2
1
) the number of template.  
In GM03349 cells, the cycle number difference is greater, two, resulting in four times 
(2
2
) more promoter A transcripts than promoter B.  As expected, Wnt5a total was larger, 
indicated by a lower cycle number than either promoter A or promoter B.   
Next, we examined the effect of TNFalpha treatment on transcript levels.  In the 
NIH3T3 cells, there was essentially no change in Wnt5a transcript, and promoter A and B 
transcripts at 6 hours (table 4).  This is in contrast to the NIH3T3 stable line treatment 
where there was an increase in promoter A and B activity (figure 10).  At 24 hours, there 
was an increase in all the target transcripts: total Wnt5a, cyclin D1, promoter A and 
promoter B transcripts (table 4).  Cyclin D1 transcription is known to be increased by 
TNFalpha stimulation and is a positive control.  The increase in total Wnt5a would be 
expected, along with an increase in either or both promoters A and B.  Both promoter A 
and B transcripts increased by about 2 fold (figure 20).  
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Table 3.  qRT-PCR Cycle Number of Wnt5a Promoters A and B Transcripts in 
NIH3T3 and GM03349 Cells. 
 
 Wnt5a Promoter A Promoter B 
NIH3T3 cells 
(6 hours untreated) 
26.34 28.31 29.27 
GM03349 cells 
(6 hours untreated) 
28.59 28.90 30.90 
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Table 4.  Fold Changes of qRT-PCR Targets in TNFalpha Treated NIH3T3 Cells. 
 
 
Fold Change 
6 hours 24 hours 
Wnt5a 0.91 1.59 
Promoter A 0.83 2.10 
Promoter B 1.30 2.02 
Cyclin D1 0.87 2.97 
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Figure 20.  qRT-PCR of NIH3T3 Cells Treated with TNFalpha.  Custom primers for mouse Wnt5a promoters A and B 
transcripts were used along with primers for Wnt5a and cyclin D1.  Cycles were normalized to the ribosomal protein cycle 
numbers and treated values compared to the untreated, normal cells.  The horizontal bar indicates no change relative to the 
control.  
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In the GM03349 cells there was an increase in Wnt5a, specific promoter A and B 
and cyclin D1 transcripts at 6 hours (figure 21).  The calculated fold changes are shown 
in table 5.  At 24 hours the relative transcript levels decreased for all but cyclin D1, but 
were slightly higher than controls.  These results support our findings with the reporter 
cell lines; both promoter A and B are affected by TNFalpha treatment. 
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Table 5.  Fold Changes of qRT-PCR Targets in TNFalpha Treated GM03349 Cells. 
  
 
Fold Change 
6 hours 24 hours 
Wnt5a 3.60 1.28 
Promoter A 3.75 1.42 
Promoter B 2.32 1.65 
Cyclin D1 2.01 0.91 
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Figure 21.  qRT-PCR of GM03349 Cells Treated with TNFalpha.  Custom primers for human Wnt5a promoters A and B 
transcripts were used along with primers for Wnt5a and cyclin D1. Cycles were normalized to the ribosomal protein cycle 
numbers and treated values compared to the untreated, normal cells. The horizontal bar indicates no change relative to the 
control. 
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CHAPTER IV 
 
DISCUSSION 
 
 
Both Wnt5a Promoters A and B are Transcriptionally Active in Distinct Cell Types 
 
Human Wnt5a alternative hpromoters A and B were analyzed separately using 
luciferase reporter vectors that were transiently transfected to determine their relative 
levels of transcriptional activity and map potential regulatory sequences by deletion 
analysis.  Our data, indicated by the similar values for firefly RLU/Renilla RLU for the 
different constructs, show that both hpromoters are equally active when assayed 
separately (figures 9 and 10).  This result suggests that hpromoter B has equal 
transcriptional potential in comparison to hpromoter A.  However, it is possible that when 
genomically linked within the Wnt5a transcription unit, the promoters are differentially 
utilized.  In fact, qRT-PCR analysis of mouse and human promoter A and B transcripts 
indicates that promoter A is utilized slightly more than promoter B.  In mouse NIH3T3 
cells, promoter A in general had one less cycle than B, indicating twice as many promoter 
A transcripts than B (table 3).  In the human GM03349 cells there was a two cycle 
difference, thus four times as many promoter A transcripts as B.  However, in the cells 
treated with TNFalpha for 6 hours, promoter A was 2.7 cycles less promoter B, resulting 
in 6.5 more promoter A transcripts than promoter B.  This observation is significant 
because the modulation of total Wnt5a in cancer cells may actually be due to differential 
promoter activity rather than other epigenetic factors.  
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To confirm the actual level of promoter A and B transcripts in situ it will be necessary to 
conduct a standard curve qRT-PCR.   
Deletion analysis of the hpromoter A and B upstream sequences support the 
conclusion that there are positive and negative acting sequences within the approximately 
2000 bp of upstream sequence being analyzed and that 350 to 400 bp is sufficient for a 
high level of expression (figures 9 and 10).  In general, the changes in expression levels 
for the different constructs varied only 2 to 3 fold for hpromoters A and B in NIH3T3 
cells and hpromoter A in Caco-2 cells.  These observations and the fact that the Wnt5a is 
activity transcribed in NIH3T3 cells, as shown by our qRT-PCR analysis, indicates that 
the gene is constitutively expressed in a fibroblast cell.  Regulation of Wnt5a in these 
cells is likely to involve slight modulations UP or DOWN in transcription rates rather 
than ON and OFF.  Based on our data, the Wnt5a gene is responding to negative and 
positive factors, which may fluctuate depending on the growth state of the cell 
population.  Induction of Wnt5a gene transcription from an OFF to an ON state is more 
likely during development.  As previously discussed, Wnt5a is involved in numerous 
developmental events, including limb, brain, intestine, and prostate formation.  To 
identify the regulatory sequences and ultimately transcriptions factors that are responsible 
for the cell-specific expression of Wnt5a during development would require alternative 
approaches. 
One unexpected result is that hpromoter B displays a different pattern of 
expression in Caco-2 than in NIH3T3.  We found that removal of upstream sequences 
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lead to continual increase of expression.  This finding suggests that negative regulatory 
sequences are being removed between the 1981-356 region of promoter B.  Although 
Caco-2 is a human cell and the Wnt5a reporter constructs are human, this does not 
explain the similar patterns of expression for hpromoter A in Caco-2 and NIH3T3 nor the 
similarity between hpromoters A and B in NIH3T3 cells.  A comparison of human 
promoter A and B upstream sequences show no homology.  It is possible, however, that 
similar transcription factor binding sites are found in each promoter that are not detected 
by a sequence homology comparison.   
    
  Activated NFkappaB Increases Promoter B Activity   
Collectively, our results from Wnt5a promoter A and B luciferase reporter stable 
cell lines and qRT-PCR plus other preliminary data support the conclusion that activated 
NFkappaB increases promoter B activity (figure 13), whereas NFkappaB does not appear 
to be involved in TNFalpha stimulation of promoter A activity (figure 12).   Using Wnt5a 
promoter A and B stable luciferase reporter lines, we found that TNFalpha treatment lead 
to increased Wnt5a promoter activity at 6 hours for both promoter A and B constructs, 
whereas only promoter B showed an increase at 24 hours (figure 11).  qRT-PCR analysis 
of Wnt5a promoter A and B specific transcripts in TNFalpha treated mouse NIH3T3 
fibroblasts and normal human fibroblast GM03349 confirmed TNFalpha increases both 
promoter A and B derived transcripts (tables 4 and 5/figures 20 and 21).  However, the 
increase was observed primarily at 6 hrs in the GM03349 cells and at 24 hours in the 
NIH3T3 cells.  At 24 hours in GM03349 cells, transcripts decreased but were slightly 
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higher than controls.  We do not have a clear explanation for the differences observed 
between the cell types and between the qRT-PCR results and stable reporter cell lines.  
One possibility is that TNFalpha signaling in normal human fibroblasts is more rapidly 
activated and terminated in comparison to the immortalized mouse fibroblasts, causing an 
earlier and less sustained increase in transcript levels.  The lack of Wnt5a promoter A and 
promoter B transcript increases in the NIH3T3 cells at 6 hours by qRT-PCR, in 
comparison to the luciferase reporter stable lines is less clear.  One explanation is the 
likely presence of concatenated promoter A and B reporter constructs in the stable lines, 
leading to greater sensitivity and detection by 6 hours after TNFalpha treatment. 
Nevertheless, our data does show that both human and mouse cell types are affected by 
TNFalpha.   
Because TNFalpha can also active MAPK signaling pathways, our results suggest 
but do not confirm the role of NFkappaB in Wnt5a promoter A and B transcription.  To 
verify that NFkappaB is responsible for the increase, we used inhibitors of NFkappaB.  
Addition of the NFkappaB inhibitor JSH-23 to promoter B NIH3T3 stable cell lines 
treated with TNFalpha reduced activity to control levels at both 6 and 24 hours (figure 
13).  Moreover, analysis of promoter B specific transcript levels by qRT-PCR in NIH3T3 
cells treated with TNFalpha alone and with JSH-23, confirmed these results; promoter B 
transcript levels increased in TNFalpha treated cells but were reduced to control levels in 
TNFalpha plus JSH-23 treated cells (preliminary data, not shown).  In contrast, JSH-23 
did not reduce the increased promoter A luciferase reporter activity or transcript levels to 
control levels in TNFalpha treated cells (figure 12).  These results suggest that the 
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increase in Wnt5a promoter A activity may be due to other pathways activated by 
TNFalpha rather than NFkappaB activation.  Surprisingly, we found NFkappaB inhibitor 
CAY10512 to increase hpromoter A and B activity rather than decrease activity as seen 
in NFkappaB inhibitor JSH-23.  One possibility for this result is the concentration is too 
high and pathways other than NFkappaB are being affected.  However, 1 uM is the same 
concentrations used in other studies in the literature.  A dose dependent assay is needed to 
determine if our results are due to high concentrations of NFkappaB inhibitor 
CAY10512. 
We have examined the upstream region of both the mouse and human promoter A 
and intron 1 of the human and mouse promoter A transcript for potential NFkappaB 
binding sites.  Promoter A intron 1 includes promoter B exon 1, intron 1, and upstream 
sequences.  Using the consensus sequence GGGRNYYYCC (R=A or G; N=A,T,C,G; 
Y=C or T) (Chen et al., 1998), three NFkappaB sites were identified in the mouse intron 
1 at positions 2585, 3190, and 3410 of the 5709 bp intron (#1 bp = 5’ nucleotide of the 
intron).  Two sites were identified in the human intron 1 at positions 1870 and 4260 of 
the 6076 bp intron.  Site 4260 is contained within the human promoter B luciferase 
reporter construct p1987.  No NFkappaB sites were identified in 4000 bp upstream of 
exon 1 or within exon 1 of the mouse Wnt5a promoter A.  One site was identified at 
position 2450 in a 4000 bp region upstream of exon 1 of human promoter A and no sites 
were identified in exon 1.  This analysis confirms that the Wnt5a gene includes 
NFkappaB binding sites in intron 1, which potentially can affect both promoter A and 
promoter B, although our data indicates that promoter B is most affected. 
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In a recent study, Ge et al., (2011) showed that interleukin-1 stimulation of 
normal chondrocytes caused an increase in both Wnt5a transcript and protein levels.  This 
increase was reduced by an inhibitor of IBa phosphorylation, required for NFkappaB 
activation.  In their study, the qRT-PCR primers detected total Wnt5a transcript levels 
and did not differentiated between the different Wnt5a isoforms (i.e. promoter A and B 
transcripts). Thus, it is possible that the change in Wnt5a transcript levels in their study 
was due to increased transcription from promoter B.  They identified an NFkappaB 
binding site immediately upstream of exon 1 of the human promoter A transcript unit.  
However, this sequence does not match the consensus NFkappaB binding sequence or 
slightly altered versions of it.  However, by ChIP analysis they did find NFkappaB 
enrichment at this sequence.  None of the potential NFkappaB binding sites within intron 
1 were analyzed.  There is one other published report of increased WNT5A protein levels 
in TNFalpha treated MKN45 gastric cancer cells (Saitoh and Katoh, 2002).  These 
studies are consistent with our findings. 
 
No Clear Evidence of MAPK Pathway Involvement in Wnt5a Transcription 
It is not possible from our results to conclude if Wnt5a promoters A and/or B 
transcription are affected by the MAPK signaling pathway.  In our experiment, NIH3T3 
cells stably transfected with the human Wnt5a promoter A and B constructs were treated 
with Ras pathway inhibitors and the level of luciferase activity determined in treated and 
untreated cells as a measure of promoter A and B activity. The inhibitors blocked activity 
of two adjacent effector kinases in the Ras pathway, MEK1/2 and ERK.  Thus, similar 
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results would be expected using the two inhibitors.   However, we found that the MEK1/2 
inhibitor U0126 did not affect promoter A activity and decreased luciferase activity B 
cell lines at 24 hours, whereas the ERK inhibitor consistently increased activity (figures 
14 and 15).  One possibility for this discrepancy is that the concentration of the U0126 
(10 uM) is high enough to affect other cellular kinases.  We also examined the level of 
mouse promoter A and B transcripts in NIH3T3 cells treated with both MEK1/2 and ERK 
inhibitors by qRT-PCR and found no effect on transcript levels for total Wnt5a and 
promoter A and B transcripts (preliminary data, not shown).  This result indicates that, at 
least in a dividing cell population, inhibition of the Ras signaling pathway does not lead 
to alterations in Wnt5a transcription from either Wnt5a alternative promoters.  To further 
resolve this question we plan to serum starve cells and then treat them with an activator 
of the Ras pathway such as epidermal growth factor and assay for changes in transcript 
levels from the Wnt5a promoters A and B.  Overall, the results presented and preliminary 
data do not clearly support involvement of Ras signaling in Wnt5a transcription.  
However, not tested in this study were the p38 and JNK pathways.   
 
Summary and Conclusions 
Our study increased understanding of Wnt5a alternative promoters A and B 
transcriptional regulation. Using the human Wnt5a alternative promoter- reporter vectors 
we found both Wnt5a Promoters A and B were transcriptionally active in NIH3T3 and 
Caco-2 cells.  However, we found both mouse and human promoter A to be more 
transcriptionally active than promoter B when assayed endogenously by qRT-PCR.  One 
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of our project goals was to determine if Wnt5a expression changes with increased 
NFkappaB activity.  We determined NFkappaB, a factor increased in cancer, may play a 
role in promoter B regulation rather than promoter A.   However, there is no clear 
evidence that the MAPK pathway is involved in Wnt5a transcription.  These studies are 
significant because they provide insight into the normal regulation of Wnt5a expression 
and how its expression might be altered in cancer.  
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APPENDIX A. 
 
PRIMER LOCATIONS FOR HUMAN WNT5A PROMOTER A LUCIFERASE 
CONSTRUCTS 
 
 
Human Wnt5a Promoter A Exon 1a and 2000 bp Upstream 
Sequence 
 
TGTGTGTGTGCGCGCGTGTGTGTGTCTTCACCTTTGACAGCTGGAGAATGCAGACGGCG
GAAAATAACTATTACGCTCCAGTGTGAGGCACTGTTTGTGGGGTGGGGCCCTCGGCGTG
CTGGAGGTAGCGGACACAAATCCACCAACCCTGCCCCTCCGGAGTCCCCAAAACCACGG
GCATCTGGAAGCGTCTAGAAATTCCGGTGCCCGGAACCCGGTTTTGCCAAACTTCGCAA
TCTCCTCACCTGAGGGCACCCGCCAAGATCTCCGTGGCAGGACCACGCATCGCGCCTCA
TGCTCTGGGCCGGAGCCAGATGAGCAATCATGCATCCCACTACCCAAGTCCCTACTACT
CTGGGGACTTTGCAGGAGGTGAGCGCCTAACCCTATCCATCAGCCCCAGTGCTTAAGTA
TCCTCCCCCAGAGGTAAGAATGAGGAGGTCCCCCATGAGGTTCCATGTCAAGGCAGCAG
TCTCCGTGGAGCCCCAGTGGGAGCGGTCTGGGATACGCGGGCGAGCCAAGGGGTCCAGG
CGGGGAAGTTGGGGTTCAGCCTCCCGCCGGTCGGTGGCTCTGGAAGGAGCGCAGACAAC
CAGGCGGCAGGCAGGCAGCGGCTGCGGAGTGGACCTCTCTCTTTCAGCAGATGCCGCGG
GGGATGGGGAACTTAGAGAAGGGGAGACAAGGAGAGTGTACCCCGCCTCCCGGCACCCC
AGCCCGTAGTACGGCTTTAAAATCCTGCAGAGTTTGTCATAGGCCGGCCTCACCACGCA
TGCGCATAGCAAAGTTGAGTTTTTTCTTTCTTCCCCCCCCTTCCCTCTCTCTTTCCAGC
CGCCCCTAGTTCTGAAACTTTAAAGAACTTTTTTCTTTCTTTCTTTCTTTCTTTTTTTT
TTTTTCTTCCTTCTGAGAACACCAGGGGAAAGAGGAGTCTGGAGAGAGGGAGGGAGAGA
GTAAGGCAGTTGGCCAGAAGGGCTGGGGGGTGGGAGGGGGGGACGCGTCCCCGCGGTCG
GTCAGTCTGTTTGCGGGGCACAGGATCGCGTGGAAATCTGCTGCGAGCTCCACGGAGCC
GCCTCCGCCGCCCAGAGCCGGGGTCCGTGCGGCAGCTGCCCAGCGAGCCCTTCCGCCGC
CGCCGTTGTGCCCGGGACCGCCCGCCTCCCGCCGGCCCGCTCTCCCGCCCCTCGGACCC
GGGCGCCAAACGAGGAGGTGGGCAGCTTCGCCGGCCATGGACCGCCGGAGCTGAGTCGC
CGCCGCGGAGCTCCGAGCTCTCGCCCTTCCCCAGCCTCGCGCCCGCGGTGCACTCGCTG
CTCTTCGCCCTTCGCCCTGGAAAAACGGGGAAAAGAGAGATCAACCCGAAGAGAGAAAG
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AACGGGATACGTGGTGGGGGGGGGGAGCCCGCGTCTCCCCTGGGTTAGTCGCACCCCTC
CAGCTCACCGCACAGCAATAAGTTCCGGGGCGACTTTCACCTATTTTGCTCCCCGTTTT
TGCCGAACCCTAAAATGAAAGGACACAATTTGGGGCTGACTCTTGCAGCTCAGATGGCG
ACTTGTGCGTTTTCAGCGGCATCTCCCGGAGAAAAAGCCATGCGCGCCTGATTGTTCTG
TGGCCCCAAAGCTGCAGCGGGGGTGTGTGTGTTGGGGTGTGTGTCTGTGTGTGTACAGA
GACGTCCACACTAACTCGCGGCTGCAGGATCAGCGTCTGGAAGCAGACGTTTCGGCTAC
AGACCCAGAGAGGAGGAGCTGGAGATCAGGAGGCGTGAGCCGCCAAGAGTTTGCAGAAT
CTGTGGTGTGAATGAACTGGGGGCACCTGGGCGCACAGATCGCCCCCCTTCCCCCGCCC
CGGGCCACAGTTGAGTAGTGGTACATTTTTTTCACCCTCTTGTGAAGAATTTCTTTTTA
TTATTATTTGTCGTAAGGTCTTTTGCACAATCACGCCCACATTTGGGGTTGGAAAGCCC
TAATTACCGCCGTCGCTGATGGACGTTGGAAACGGAGCGCCTCTCCGTGGAACAGTTGC
CTGCGCGCCCTCGCCGGACCGGCGGCTCCCTAGTTGCGCCCCGACCAGGCCCTGCCCTT
GCTGCCGGCTCGCGCGCGTCCGCGCCCCCTCCATTCCTGGGCGCATCCCAGCTCTGCCC
CAACTCGGGAGTCCAGGCCCGGGCGCCAGTGCCCGCTTCAGCTCCGGTTCACTGCGCCC
GCCGGACGCGCGCCGGAGGACTCCGCAGCCCTGCTCCTGACCGTCCCCCCAGGCTTAAC
CCGGTCGCTCCGCTCGGATTCCTCGGCTGCGCTCGCTCGGGTGGCGACTTCCTCCCCGC
GCCCCCTCCCCCTCGCCATG 
 
Black = upstream sequence 
 
Red=Exon 1 
 
ATG = start of translation 
Underlined Blue = Forward PCR Primers 
Underlined Red = Reverse PCR Primer 
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APPENDIX B. 
 
PRIMER LOCATIONS FOR HUMAN WNT5A PROMOTER B LUCIFERASE 
CONSTRUCTS 
 
 
Human Wnt5a Upstream of Exon1b and Exon 2(Promoter B) 
 
TTGCACTGGGATTGAAGAGGGAAGAGGGCCAAGGTGTTTCCGGGCAAGCGGCGGGGTTA
AGTGGAGATGCGACTCGTGAGGCTCTCCTTTCCGATCCCCCTTTGGGACACCCTCTGCC
TACCTCTACCCTGGAGCCAGGGAGACCCAAGTCTTGGTGACCGGATGGGCCCGCTCTCA
GTTGGCCTGGGCTCTGGGAACTGGTGGACTCTCCCTGGGGGCTTCGGGCTGGGAGTGGG
TTCGGTTTGTGTGGCTTCGGCTCTAACAAAGAGATCCGCTGTAATCCGCCGAATCTGTT
ATCAATTTCTCTGCTGCTTGAGCCCCGCCCCACGCGCCCCGCTCGCCGCGAAGCTTGGA
AAGTGCACGCGGCCAGCACCAATCTGGGCCGCTGACTCGGAAACATGTCGCAGCGTGTG
TGTCTATGCACGCGTGTGAGTGTGTAAATGTGCACGAGTGTGAATGTGTATGATGTGTG
TGCACGCGGCATCGGCTGCCCTTGGGGAGAGTTGACTTTGCAGCCTGGGCTGCGCGAGA
AGCAGACTTTGCAGCCCACTCCCTCCCCTGGAGGAAATTTGACACTTAGGGCGGGGGTG
GGGAGATAGCCGGAGCCTTCTCTCTCCTAGCTGGGGAAACCCCAGATTTCCATTCTCCA
GGATGCGCCCCCCAGCTTTGCAGCGTTTTGGGGACAACTGGGCCTTGGGTGTGGAGCCC
TGCTTAGCAGGCGCTGGGGACCACATAAGCATTTCCTCTTTGAGAAGCCCCGAAGCGTC
CAGGCCAAAGGGGCGGCTCACGGAGAAAAACCTTGGCACGCCCCTGAGCCCCATAGCTT
TACCAGGGCTGCCTAGGTCCCCTCTGCCCCTTTTACGGCACAGGTTCCAAGCCAGGCTC
TTCCACCGCCTTAAAGAGGCTCACCTTTCTTTTCTTTTCTGTGGAAGGGGCTCCTTCAG
GGGCTATGGGCGATGCAGTGCGGCAGGGTTAGACTTACGTGTAAGGGGATTTTTAAAAC
CCGCTCCTCCCACCCGCACCCGCCACCTACTCGCTCCGCCGCCGCCTACAGGTGGAGAA
GTCACCAGTGGGGAGGAACGGCAGCGGAAGCTTCCAAGGCCAACTCCTACCCCTGAAAT
TCTTCAGGAAGGGAACCTTCGCCGCTGGGGGCCTCTTTGCCCTGGAATCGATGCGCCCA
GCTGCGGCTCGGAAGCCAGCGCCTCTGGCCCCGTCTGGACTCATCTGCAAGGGCTCTGG
CCTCGCCCCGCACCCCCACCTTTCGGCACTGACCGAACCAAGTCTGAGTTGGGCTGGAG
AGGCTAGACTGGAGGCAGGGTGGCAGAGTTCCAACGACAGGCTCGCAGTGCCGCGATGG
CAAAGTGGCCCACAACCCCAGATCAGGACCAAGGGAAACTGGAGTCTCTCTGGGCCTCC
CATCTCCTCCCTCCCTGGCAGCTGCCAGGTGTGGGGTGGGAGGGAGAGTGAAAAATCAG
AATTTGGGAGAAAGCTGTGGGGAGGGCAGGGAAGGGATCTTCTCCCCGGGGAAGCGAGA
CCCAGACTCCCTTCTTTCCTCTAGGGTTCCATCCCTTCTCTCAGTCCGTGGAAGAGGCC
ACAGGCGACGCGGGCGAGGGTGGCACTCTTTTCCAGTTTCCTTGGTTGGGAGACCCGAC
CTCTCTCTCCATTATCCCCTAGGGCCCCCATCTCCTTCTCCCCTCCCTAGTCTGGCTGA
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AGAACGTCCTTAAGGAAATCCGGGCTGCTCTTCCCCATCTGGAAGTGGCTTTCCCCACA
TCGGCTCGTAAACTGATTATGAAACATACGATGTTAATTCGGAGCTGCATTTCCCAGCT
GGGCACTCTCGCGCGCTGGTCCCCGGGGCCTCGCCCCCCACCCCCTGCCCTTCCCTCCC
GCGTCCTGCCCCCATCCTCCACCCCCCGCGCTGGCCACCCCGCCTCCTTGGCAGCCTCT
GGCGGCAGCGCGCTCCACTCGCCTCCGTGCTCCTCTCGCCCATGGAATTAATTCTGGCT
CCACTTGTTGCTCGGCCCAGGTTGGGGAGAGGACGGAGGGTGGCCGCAGCGGGTTCCTG
AGTGAATTACCCAGGAGGGACTGAGCACAGCACCAACTAGAGGGGGGCCAGGGGGTGCG
GGACTCGAGCGAGCAGGAAGGAGGCAGCGCCTGGCACCAGGGCTTTGACTCAACAGAAT
TGAGACACGTTTGTAATCGCTGGCGTGCCCCGCGCACAGGATCCCAGCGAAATCAGATT
TCCTGGTGAGGTTGCGTGGGTGGATTAATTTGGAAAAAGAAACTGCCTATATCTTGCCA
TCAAAAAACTCACGGAGGAGAAGCGCAGTCAATCAACAGTAAACTTAAGAGACCCCGGA
TGCTTCCGTTGTTTAAACTTGTATGCTTGAAAATTATCTGAGAGGCAATAAACATCTGC
TCCTTTCTTCCCTCTCCAGAAGTCCATTGGAATATTAAGCCCAGGAGTTGCTTTGGGGA
TGGCTGGAAGTGCAATGTCTTCCAAGTTCTTCCTAGTGGCTTTGGCCATATTTTTCTCC
TTCGCCCAGGTTGTAATTGAAGCCAATTCTTGGTG 
 
Black = upstream 
Red  = exons 
Green = intron  
ATG = start of translation 
Underlined Blue = Forward PCR Primers 
Underlined Red = Reverse PCR Primer  
 
